A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Abstract

Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases. TNBC is highly aggressive and associated with poor prognosis. The present study aimed to compare gene expression between TNBC patients with pathological complete response (pCR) and those with not complete response (nCR) to neoadjuvant chemotherapy. Microarray data of 16 TNBC patients received neoadjuvant chemotherapy were identified from the Gene Expression Omnibus database and 10 patients of them had pCR. We found that 250 coding genes and 155 long noncoding RNAs (lncRNAs) were statistically differentially expressed between patients with pCR and nCR. Receiver operator characteristic curve and area under the curve (AUC) were calculated to assess predictive value of differentially expressed genes. A gene signature of three coding genes and two lncRNA was developed: 2.318*TCF3 + 7.349*CREB1 + 0.891*CEP44 + 0.091*NR_023392.1 + 1.424*NR_048561.1 − 106.682. The gene signature was further validated and had an AUC = 0.829. In summary, we profiled gene expression in pCR patients and developed a gene signature, which was effective to predict pCR among TNBC patients received neoadjuvant chemotherapy.

Long non-coding RNA-based signatures to improve prognostic prediction of breast cancer

“…[ 8 9 10 ] Increasing studies have found that lncRNAs exist abnormal expression and related to prognosis in BC. [ 11 12 13 ] However, there are few studies on the prognostic value of uniting biomarkers and other clinical indicators.…”

Systematic characterization of non‐coding RNAs in triple‐negative breast cancer

“…Moreover, lncRNAs not only participate in the process of chemoresistance, but can also be used for predicting the response to neoadjuvant chemotherapy in TNBC. Zheng et al 110 systematically compared gene expression between TNBC patients with pathological complete response and those without a complete response to neoadjuvant chemotherapy and ultimately developed a gene signature of 2 coding genes and 3 lncRNAs to predict the response to neoadjuvant chemotherapy of TNBC patients.…”

A Novel DNA Damage Repair-Related Gene Signature for Predicting Glioma Prognosis

“…13 Recently, plenty of gene signatures have become biomarkers for guiding treatment in various cancers. [14][15][16] Multigene prognostic sets can predict the tumor prognosis more accurately than a single gene, which enable more effective treatment of cancer patients. 17,18 Identifying the hallmark gene signature is important for clinical application and precision medicine of cancers.…”